We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and Provides Varoglutamstat and Strategic Updates Vivoryon Therapeutics N.V. Reports Full Year 2023 Financial Results and...
Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and Operational Progress on April 24, 2024 Vivoryon Therapeutics N.V. to Report Full Year 2023 Financial Results and...
Vivoryon Therapeutics N.V. Announces Changes to Board Composition Vivoryon Therapeutics N.V. Announces Changes to Board Composition Halle (Saale) / Munich, Germany, March 15, 2024 – Vivoryon...
Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of Varoglutamstat in Early Alzheimer’s Disease Vivoryon Therapeutics N.V. Provides Update on VIVIAD Phase 2b Study of...
Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Vivoryon Therapeutics N.V. to Host Investor Meetings in January 2024 Halle (Saale) / Munich, Germany, January 8, 2024 –...
Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and Highlights Operational Progress Vivoryon Therapeutics N.V. Reports Third Quarter 2023 Financial Results and...
Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational Progress on December 6, 2023 Vivoryon Therapeutics N.V. to Report Q3 2023 Financial Results and Operational...
Vivoryon Therapeutics N.V. to Present at Upcoming Investor Conference Halle (Saale) / Munich, Germany, November 7, 2023 – Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7...
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision Vivoryon Therapeutics...
Vivoryon Therapeutics N.V. Reports Positive Outcome from Independent Data Safety Monitoring Board with Unanimous Decision for VIVA-MIND U.S. Study of Varoglutamstat in Alzheimer’s Disease to...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.283 | 60.2127659574 | 0.47 | 0.999 | 0.45 | 1677262 | 0.80183056 | DE |
4 | 0.213 | 39.4444444444 | 0.54 | 0.999 | 0.41 | 572463 | 0.72969993 | DE |
12 | -7.727 | -91.1202830189 | 8.48 | 9.93 | 0.41 | 765752 | 1.02078 | DE |
26 | -6.807 | -90.0396825397 | 7.56 | 9.93 | 0.41 | 392755 | 1.69398871 | DE |
52 | -12.747 | -94.4222222222 | 13.5 | 19.56 | 0.41 | 229626 | 3.4768114 | DE |
156 | -14.127 | -94.939516129 | 14.88 | 23.25 | 0.41 | 118957 | 6.79672641 | DE |
260 | -4.837 | -86.5295169946 | 5.59 | 23.25 | 0.41 | 105876 | 7.2123231 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions